• Allison T Lanfear, Mohanad Hamandi, Joy Fan, J Michael DiMaio, and Timothy J George.
• Cardiovascular Research, Baylor Scott & White The Heart Hospital, Plano, Texas.
• J Card Surg. 2020 Jan 1; 35 (1): 180-187.

BackgroundThe HeartMate 3 left ventricular assist device (LVAD) is a novel, intrapericardial, centrifugal-flow pump with a fully magnetically-levitated rotor designed to provide hemodynamic support in patients with end-stage heart failure. Unique aspects of this LVAD have allowed for improved hemocompatibility and the development of minimally-invasive implantation techniques.MethodsThe PubMed, EMBASE, and Google Scholar databases were searched for publications relating to the HeartMate 3 device, with a focus on hemocompatibility related outcomes, anticoagulation management, and surgical techniques.ResultsNine articles analyzing hemocompatibility related outcomes from two clinical trials, two clinical studies, and one registry series were identified.ConclusionHeartMate 3 has reduced the rate of disabling stroke and pump thrombosis. However, despite increased hemocompatibility due to specialized design features, the residual risk of both surgical, and gastrointestinal bleeding remains a major adverse outcome. Different anticoagulation management and surgical techniques have been evaluated to address the remaining complications.© 2019 Wiley Periodicals, Inc.

12 keywords...

hide…